The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kalinina S.L.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Lyanguzov A.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Sergunina O.Yu.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Ignatyev S.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Kovtunova M.E.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Minaeva N.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Paramonov I.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Comparative assessment of different central venous access devices in patients with hemoblastosis

Authors:

Kalinina S.L., Lyanguzov A.V., Sergunina O.Yu., Ignatyev S.V., Kovtunova M.E., Minaeva N.V., Paramonov I.V.

More about the authors

Journal: Russian Journal of Anesthesiology and Reanimatology. 2021;(4): 91‑96

DOI: 10.17116/anaesthesiology202104191

Read: 1769 times

Download PDF (RU)
Contact the author
Table of contents

COMPARATIVE ASSESSMENT OF DIFFERENT CENTRAL VENOUS ACCESS DEVICES IN PATIENTS WITH HEMOBLASTOSIS
COMPARATIVE ASSESSMENT OF DIFFERENT CENTRAL VENOUS ACCESS DEVICES IN PATIENTS WITH HEMOBLASTOSIS

To cite this article:

Kalinina SL, Lyanguzov AV, Sergunina OYu, Ignatyev SV, Kovtunova ME, Minaeva NV, Paramonov IV. Comparative assessment of different central venous access devices in patients with hemoblastosis. Russian Journal of Anesthesiology and Reanimatology. 2021;(4):91‑96. (In Russ.)
https://doi.org/10.17116/anaesthesiology202104191

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cost of supportive cancer care in the Russian Fede­ration. Part 2. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):63-73
History creates man, and man creates history. On the 125th anni­versary of the P.A. Herzen Moscow Onco­logy Research Institute. P.A. Herzen Journal of Onco­logy. 2024;(6):5-11
Use of a new tetrapeptide analgesic at the stages of anti­tumor therapy. P.A. Herzen Journal of Onco­logy. 2024;(6):23-32
Primary outcomes after major anatomical liver rese­ctions in infa­nts at the National Children’s Medi­cal Center. Piro­gov Russian Journal of Surgery. 2025;(4):86-94
Approaches to the digi­tization of clinical guidelines. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):39-47
Dyna­mics of the main indi­cators of medi­cal care to the popu­lation of the Russian Fede­ration for the period 1993—2023 in the “Oncology” profile. P.A. Herzen Journal of Onco­logy. 2025;(3):71-77
Obje­ctification of complaints of patients dissatisfied with the result of direct aesthetic restoration of teeth. Russian Journal of Stomatology. 2025;(3):5-12
Inci­dence of complications in periorbitoplasty. Plastic Surgery and Aesthetic Medi­cine. 2025;(3-2):14-33
Clinical and economic analysis of nutritional support in the perioperative treatment of lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(5):54-58
Abstract:

OBJECTIVE

To analyze economic efficiency of various central venous access devices and quality of life associated with their use in patients with hemoblastosis.

MATERIAL AND METHODS

The study included 154 patients of Hematology Hospital of the Kirov Research Institute of Hematology and Blood Transfusion with various central venous access devices installed in 2017-2019. Group 1 included patients with non-tunneled, tunneled central venous catheters (CVCs) and peripherally implantable central venous catheters (PIC catheters), group 2 — patients with totally implantable venous access port systems (TIVAPS). We analyzed time of insertion of each type of device, cost per 1 catheter-day and patient subjective assessment of central venous access devices (Likert scale).

RESULTS

CVCs have been used for 21.5±5.8 days, tunneled CVCs — 152.2±28.4 days, PIC catheters — 97.7±20.1 days, port systems — 589.3±225.7 days. Time of TIVAPS insertion was significantly longer compared to devices with cutaneous placement of proximal part of catheter (F=5.33; p=0.000). The cost of TIVAPS was the lowest compared to other devices per 1 catheter-day. TIVAPS cause less discomfort at the site of installation (p=0.03) and limit daily life opportunities of patients to a lesser extent compared to systems with cutaneous arrangement of proximal part of catheter (p=0.012).

CONCLUSION

TIVAPS optimizes the cost of venous access in patients with hemoblastosis considering long-term period of treatment. Venous port systems in patients with hemoblastosis minimally restrict daily activity of patients and ensure an acceptable quality of life.

Keywords:

hematology
oncology
central venous access
totally implantable venous access port systems
cost effectiveness
patient satisfaction

Authors:

Kalinina S.L.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Lyanguzov A.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Sergunina O.Yu.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Ignatyev S.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Kovtunova M.E.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Minaeva N.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Paramonov I.V.

Kirov Research Institute of Hematology and Blood Transfusion of the FMBA of Russia

Received:

22.01.2021

Accepted:

14.02.2021

Close metadata

References:

  1. Youn JK, Jung K, Park T, Kim HY, Jung SE. The effect of Absolute Neutrophil Count (ANC) on early surgical site infection in Implanted Central Venous Catheter (ICVC). Journal of Pediatric Surgery. 2020;55(7):1344-1346. https://doi.org/10.1016/j.jpedsurg.2019.09.035
  2. Rykov MY, Polyakov VG. Implantable venous ports in pediatric oncology: experience of single institution in Russia. The Journal of Vascular Access. 2016;17(4):345-347.  https://doi.org/10.5301/jva.5000556
  3. Sakai T, Kohda K, Konuma Y, Hiraoka Y, Ichikawa Y, Ono K, Horiguchi H, Tatekoshi A, Takada K, Iyama S, Kato J. A role for peripherally inserted central venous catheters in the prevention of catheter-related blood stream infections in patients with hematological malignancies. International Journal of Hematology. 2014;100(6):592-598.  https://doi.org/10.1007/s12185-014-1677-9
  4. Cesaro S, Cavaliere M, Pegoraro A, Gamba P, Zadra N, Tridello G. A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients. Annals of Hematology. 2016;95(5):817-825.  https://doi.org/10.1007/s00277-016-2634-x
  5. Lyanguzov AV, Kalinina SL, Sergunina OYu, Ignatyev SV, Tselousova OM, Vaskina EA, Tataurova IP. Use of totally implantable venous port systems in children hematology clinic. Rossijskij zhurnal detskoj gematologii i onkologii. 2020;7(2):35-41. (In Russ.). https://doi.org/10.21682/2311-1267-2020-7-2-35-41
  6. Heibl C, Trommet V, Burgstaller S, Mayrbaeurl B, Baldinger C, Koplmüller R, Kühr T, Wimmer L, Thaler J. Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. European Journal of Cancer Care. 2010;19(5):676-681.  https://doi.org/10.1111/j.1365-2354.2009.01115.x
  7. Rykov MYu, Men TKh, Susuleva NA, Polyakov VG. Venous Access in Treating Children with Cancer: 5-years Experience of the Institute of Pediatric Oncology and Hematology. Onkopediatriya. 2015;2(3):193-204. (In Russ.). https://doi.org/10.15690/onco.v2.i3.1397
  8. Lyanguzov AV, Kolotilov LV, Zagoskina TP. Rhabdomyolysis in Patients with Hemoblastoses during Intensive Chemotherapy. Obshchaya reanimatologiya. 2009;5(4):60-65. (In Russ.). https://doi.org/10.15360/1813-9779-2009-4-60
  9. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp ME, Saint S; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. Clinical Infectious Diseases. 2011;52(9):162-193.  https://doi.org/10.1093/cid/cir257
  10. Hansen BA, Wendelbo Ø, Bruserud Ø, Hemsing AL, Mosevoll KA, Reikvam H. Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterranean Journal of Hematology and Infectious Diseases. 2020;12(1):e2020009. https://doi.org/10.4084/MJHID.2020.009
  11. Rajendranath R, Balasubramaniyum VK, Vijayakumar V, Ganesan P, Tenali GS. Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India. Indian Journal of Cancer. 2014;51(4):481-486.  https://doi.org/10.4103/0019-509X.175303
  12. Samaras P, Dold S, Braun J, Kestenholz P, Breitenstein S, Imhof A, Renner C, Stenner-Liewen F, Pestalozzi BC. Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. Oncology. 2008;74(3-4):237-244.  https://doi.org/10.1159/000151393
  13. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews. 2007;20(1):133-163.  https://doi.org/10.1128/CMR.00029-06
  14. Girmenia C, Finolezzi E, Federico V, Santopietro M, Perrone S. Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options. Mediterranean Journal of Hematology and Infectious Diseases. 2011;3(1):e2011013. https://doi.org/10.4084/MJHID.2011.013
  15. Kimura M, Araoka H, Yamamoto H, Asano-Mori Y, Nakamura S, Yamagoe S, Ohno H, Miyazaki Y, Abe M, Yuasa M, Kaji D, Kageyama K, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Uchida N, Izutsu K, Wake A, Taniguchi S, Yoneyama A. Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital. Antimicrobial Agents and Chemotherapy. 2017;61(4):e01791-16.  https://doi.org/10.1128/AAC.01791-16
  16. Spirin MV, Galstyan GM, Drokov MYu, Kuzmina LA, Klyasova GA, Parovichnikova EN, Savchenko VG. Provision of central venous access during allogenic haematopoetic stem cell transplantation. Gematologiya i transfuziologiya. 2019;64(4):396-411. (In Russ.). https://doi.org/10.35754/0234-5730-2019-64-4-396-411
  17. Perez AW, Watchmaker JM, Brown DB, Banovac F. Association between Periprocedural Neutropenia and Early Infection-related Chest Port Removal. Radiology. 2019;291(2):513-518.  https://doi.org/10.1148/radiol.2019182175
  18. Johnson EJ. Is It Appropriate to Place Subcutaneous Chest Ports in Patients with Neutropenia? Radiology. 2019;291(2):519-520.  https://doi.org/10.1148/radiol.2019190095
  19. VanHouwelingen LT, Veras LV, Lu M, Wynn L, Wu J, Prajapati HJ, Gold RE, Murphy AJ, Fernandez-Pineda I, Gosain A, Pui CH, Davidoff AM. Neutropenia at the time of subcutaneous port insertion may not be a risk factor for early infectious complications in pediatric oncology patients. Journal of Pediatric Surgery. 2019;54(1):145-149.  https://doi.org/10.1016/j.jpedsurg.2018.10.024
  20. Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. Cancer Treatment and Research. 2019;179: 11-36.  https://doi.org/10.1007/978-3-030-20315-3_2
  21. Ignatyev SV, Zotina EN, Fokina ES, Lyanguzov AV, Lagunova OR, Ivashkina EP. Procoagulantive state in patients with non-Hodgkin’s lymphomas. Tromboz, gemostaz i reologiya. 2018;3(75):35-40. (In Russ.). https://doi.org/10.25555/THR.2018.3.0849
  22. Tran H, Arellano M, Chamsuddin A, Flowers C, Heffner LT, Langston A, Lechowicz MJ, Tindol A, Waller E, Winton EF, Khoury HJ. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leukemia and Lymphoma. 2010;51(8):1473-1477. https://doi.org/10.3109/10428194.2010.481065
  23. Taxbro K, Hammarskjöld F, Thelin B, Lewin F, Hagman H, Hanberger H, Berg S. Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial. British Journal of Anaesthesia. 2019;122(6):734-741.  https://doi.org/10.1016/j.bja.2019.01.038
  24. Okazaki M, Oyama K, Kinoshita J, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fushida S, Ohta T. Incidence of and risk factors for totally implantable vascular access device complications in patients with gastric cancer: A retrospective analysis. Molecular and Clinical Oncology. 2019;11(4):343-348.  https://doi.org/10.3892/mco.2019.1897
  25. Lyanguzov AV, Kalinina SL, Sergunina OYu, Ignatyev SV, Rasin MP. Experience of using totally implantable venous access devices in patients with hemoblastosis. Meditsinskij vestnik Severnogo Kavkaza. 2020;15(4):484-488. (In Russ.). https://doi.org/10.14300/mnnc.2020.15113
  26. Carde P, Cosset-Delaigue MF, Laplanche A, Chareau I. Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. European Journal of Cancer and Clinical Oncology. 1989;25(6):939-944.  https://doi.org/10.1016/0277-5379(89)90151-x
  27. Wu O, Boyd K, Paul J, McCartney E, Ritchie M, Mellon D, Kelly L, Dixon-Hughes J, Moss J. Hickman catheter and implantable port devices for the delivery of chemotherapy: a phase II randomised controlled trial and economic evaluation. British Journal of Cancer. 2016;114(9):979-985.  https://doi.org/10.1038/bjc.2016.76
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.